Abstract
Exosomes, small membrane vesicles (30-100 nm) of endocytic origin secreted by most cell types, contain functional biomolecules, which can be horizontally transferred to recipient cells. Exosomes bear a specific protein and lipid composition, and carry a select set of functional mRNAs and microRNAs. Recently, our group has shown that c-Met shed in exosomes can promote a proangiogenic and prometastatic phenotype in bone marrow-derived progenitor cells during melanoma progression. In previous research, retrotransposon RNA transcripts, single-stranded DNA (ssDNA), mitochondrial DNA, and oncogene amplifications (i.e., c-myc) have been detected in microvesicles. In this report, we provide evidence that tumor-derived exosomes carry double-stranded DNA (dsDNA), as demonstrated through two different approaches, using enzymatic methods (dsDNA-specific shrimp DNase) and physical/structural studies (atomic force microscopy, AFM). Furthermore, we show that exosomal DNA (exoDNA) represents the entire genome and reflects the mutational status of parental tumor cells. We also highlight the translational value of exoDNA in tumor-derived exosomes for its potential usefulness as a circulating biomarker in the early detection of cancer and metastasis.
Introduction
Detecting cancer early and monitoring its genetic evolution is a major challenge in oncology. While "liquid biopsies"—the analysis of biomarkers in blood or other fluids—are promising, researchers have struggled to find stable, representative genetic material. Exosomes are small (30-100 nm) membrane vesicles that travel through the bloodstream. While they were known to carry RNA and proteins, their DNA content was poorly understood. Previous studies suggested they might contain single-stranded DNA (ssDNA) or mitochondrial DNA, but the evidence was inconsistent. This study aims to definitively characterize the DNA within exosomes and determine if it can serve as a reliable surrogate for the tumor's actual genome.
Methods
The authors employed a multi-pronged approach to validate the nature of exoDNA:
- Enzymatic Digestion: Specific enzymes—S1 nuclease (digests ssDNA) and Shrimp dsDNase (digests dsDNA)—were used to treat DNA extracted from exosomes.
- Physical Imaging: Atomic Force Microscopy (AFM) was used to directly visualize DNA molecules, confirming dimensions matching double-stranded helices.
- Genomic Characterization: Whole-Genome Sequencing (WGS) and Comparative Genomic Hybridization (CGH) were used to assess genomic representation.
- Mutational Analysis: Allele-Specific PCR (AS-PCR) was used to identify "driver" mutations (e.g., BRAF V600E, EGFR) in exoDNA from various cancer models.
Results
Characterization of Exosomal DNA
The study demonstrated that dsDNA is the dominant cargo in tumor-derived exosomes. Unlike previous reports focusing on ssDNA, enzymatic assays and AFM confirmed the presence of high-molecular-weight dsDNA. Crucially, exoDNA is not composed of random fragments but represents the entire genome in an unbiased manner, covering both coding and non-coding regions across all chromosomes.
Mutational Mirroring and Clinical Potential
A key finding is that exoDNA perfectly reflects the mutational status of the parent tumor. The researchers achieved 100% detection of EGFR mutations in exoDNA isolated from non-small cell lung cancer (NSCLC) cell lines. Furthermore, in pre-clinical mouse models, the BRAF V600E mutation was successfully detected in circulating exosomes isolated from plasma. Tumor cells were found to secrete significantly more exoDNA (approximately 20-fold) than normal fibroblasts, enhancing its specificity as a cancer biomarker.
Discussion
The discovery of whole-genome dsDNA within exosomes provides a powerful tool for non-invasive "liquid biopsies." While electron microscopy revealed that only about 10% of exosomes contain DNA, the high concentration of exoDNA in cancer-derived vesicles makes it a viable target for early detection and treatment monitoring.
Future work is needed to address the heterogeneity of DNA packaging and the biological mechanisms behind it. It remains unclear how genomic DNA is packaged into endocytic vesicles or if it plays a functional role in horizontal gene transfer. Clinical validation in human patients will be the next critical step to determine if exoDNA can truly replace or augment traditional tissue biopsies.
Summary updated